Catalyst Pharmaceuticals’ (CPRX) Overweight Rating Reiterated at Stephens

Stephens reaffirmed their overweight rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a report released on Thursday morning,Benzinga reports. They currently have a $33.00 price objective on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. Bank of America restated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Robert W. Baird assumed coverage on Catalyst Pharmaceuticals in a report on Tuesday, February 4th. They issued an “outperform” rating and a $28.00 price target for the company. HC Wainwright boosted their price objective on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Finally, StockNews.com cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 11th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $32.00.

Catalyst Pharmaceuticals Stock Up 5.2 %

Shares of CPRX stock opened at $21.66 on Thursday. The company has a 50 day moving average of $22.21 and a 200-day moving average of $21.40. Catalyst Pharmaceuticals has a 12-month low of $14.16 and a 12-month high of $24.64. The firm has a market cap of $2.58 billion, a P/E ratio of 18.36, a PEG ratio of 3.31 and a beta of 0.80.

Insider Activity

In related news, insider Steve Miller sold 50,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the sale, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. This represents a 6.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Steward Partners Investment Advisory LLC purchased a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $27,000. Farther Finance Advisors LLC grew its stake in Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,495 shares during the period. Larson Financial Group LLC raised its holdings in Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 2,994 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Catalyst Pharmaceuticals during the fourth quarter valued at $65,000. Finally, KBC Group NV boosted its holdings in shares of Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,542 shares in the last quarter. 79.22% of the stock is owned by institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.